Nirsevimab: Sanofi, AstraZeneca and Sobi simplify contractual agreements
Modification of existing collaboration agreement with AstraZeneca gives Sanofi full commercial control of nirsevimab and enhanced agility in the U.S.
Existing collaboration agreement with AstraZeneca remains in place for nirsevimab activities ex-U.S.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.